terizidone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2602 | 25683-71-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
minor descriptor (1975-1984); on-line & Index Medicus search OXAZOLES (1975-1984); RN given refers to parent cpd without isomeric designation
|
Drug dosage:
None
ADMET properties:
None
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Myelosuppression | 67.18 | 48.81 | 19 | 542 | 23684 | 63464777 |
| Polyneuropathy | 61.50 | 48.81 | 16 | 545 | 14573 | 63473888 |
| Myopathy | 55.61 | 48.81 | 14 | 547 | 11177 | 63477284 |
| Neuropathy peripheral | 53.65 | 48.81 | 24 | 537 | 113643 | 63374818 |
| Drug resistance | 49.97 | 48.81 | 15 | 546 | 22918 | 63465543 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Myelosuppression | 71.98 | 54.16 | 21 | 450 | 19244 | 34937216 |
| Drug resistance | 57.65 | 54.16 | 19 | 452 | 25908 | 34930552 |
| Electrocardiogram QT prolonged | 56.43 | 54.16 | 21 | 450 | 40931 | 34915529 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Myelosuppression | 134.57 | 50.49 | 40 | 1000 | 40256 | 79703092 |
| Polyneuropathy | 112.04 | 50.49 | 31 | 1009 | 24120 | 79719228 |
| Drug resistance | 75.09 | 50.49 | 26 | 1014 | 42187 | 79701161 |
| Anaemia | 68.87 | 50.49 | 52 | 988 | 444963 | 79298385 |
| Electrocardiogram QT prolonged | 59.05 | 50.49 | 27 | 1013 | 90359 | 79652989 |
| Neuropathy peripheral | 53.13 | 50.49 | 29 | 1011 | 141276 | 79602072 |
| Psychotic disorder | 52.96 | 50.49 | 20 | 1020 | 41382 | 79701966 |
| Bicytopenia | 51.53 | 50.49 | 12 | 1028 | 4658 | 79738690 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J04AK03 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Other drugs for treatment of tuberculosis |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.06 | acidic |
| pKa2 | 7.66 | acidic |
| pKa3 | 3.32 | Basic |
| pKa4 | 2.72 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D07247 | KEGG_DRUG |
| C0145184 | UMLSCUI |
| CHEBI:135278 | CHEBI |
| CHEMBL2107553 | ChEMBL_ID |
| DB12954 | DRUGBANK_ID |
| C100142 | MESH_SUPPLEMENTAL_RECORD_UI |
| 65720 | PUBCHEM_CID |
| 1707 | INN_ID |
| 1199LEX5N8 | UNII |
| 57047 | RXNORM |
| 005992 | NDDF |
Pharmaceutical products:
None